Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.This report on Pirfenidone provides comprehensive ...

Video content above is prompted by the following: How do nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating IPF?

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

发表在《科学》期刊上的一份新研究或许解释了为何男性寿命比女性短。研究发现，随着年龄增长，许多男性出现性染色体丧失的症状，造成心肌纤维化而引发致命的心脏衰竭。

Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $1.03 billion market cap biotech company, executed sales of common stock valued at a total of $46,360 over two consecutive days, ...

Current treatment options, including antifibrotic drugs such as pirfenidone and nintedanib, can decelerate disease progression but are not curative, leaving an unmet need for therapies that can halt ...

After hours: February 14 at 4:01:48 PM EST Loading Chart for GYRE ...